Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Heptares Therapeutics on its Sale to Sosei Group

February 27, 2015

LONDON, February 27, 2015 — Covington advised Heptares Therapeutics Limited on its announced sale to Sosei Group, a Tokyo-listed Japanese biopharmaceutical company with operations in Japan and the UK. Consideration consisted of $180 million cash at closing and up to an additional $220 million contingent upon the successful progression of Heptares’ pipeline and platform.
Heptares is a clinical-stage private UK-based biotechnology company focused on creating novel medicines targeting G protein-coupled receptors, a superfamily of membrane proteins found in every cell in the body that are crucial to communication between cells. It has a clinical and preclinical pipeline of potentially transformative new medicines targeting serious diseases with major unmet need, e.g. Alzheimer’s disease, ADHD, metabolic disease, schizophrenia, migraine, and others, and a high potential StaR® drug discovery platform.

The core Covington team included James Gubbins, Guy Dingley, Tom Goodman and Aysha Qureshi. Further support was provided by Kristian Wiggert and Emma Heffernan (corporate); Chris Bracebridge and Antonio Michaelides (employment); Morag Peberdy, Daniel Pavin, Lucinda Osborne and David Dennis (IP); Hilary Prescott (property) and Sarah Cowlishaw (regulatory).

Share this article: